Literature DB >> 7523516

Bw4-reactive and Bw6-reactive antibodies recognize multiple distinct HLA structures that partially overlap in the alpha-1 helix.

C T Lutz1, K D Smith, N S Greazel, B E Mace, D A Jensen, J A McCutcheon, N E Goeken.   

Abstract

Bw4 and BW6 epitopes are expressed by mutually exclusive sets of HLA-B alleles and some HLA-A and HLA-C alleles. To test whether antithetical structures are required to express Bw4 and Bw6 epitopes, we measured binding of Bw4-reactive and Bw6-reactive alloantibodies and mAbs to HLA-B7 variants. A triple substitution of HLA-B7 alpha-1 helix residues 80, 82, and 83 created Bw4 and destroyed Bw6 epitopes detected by alloantibodies and mAbs. Both Bw4-reactive and Bw6-reactive mAbs competed for binding to HLA-B7 variants with single substitutions at residues 82 and 83. Substitutions of residues H93 and D119 which form a salt bridge in HLA-A2 also permitted binding by both Bw4-reactive and Bw6-reactive mAbs, suggesting that Bw4 and Bw6 epitopes are conformationally dependent. Six Bw4-reactive mAbs showed four distinct patterns of binding to HLA-B7 variants. Detailed analysis of 74 HLA-B7 single-residue variants showed that Bw6-reactive SFR8-B6 binding was prohibited by mutations altering the distal end of the alpha-1 helix and the nearby connecting loop. In contrast, Bw6-reactive BB7.6 binding required both alpha-1 and alpha-2 helix residues. Thus, Bw4-reactive and Bw6-reactive Abs recognize multiple distinct HLA structures that partially overlap in the alpha-1 helix. As both Bw4 and Bw6 epitopes are expressed by some HLA-B7 variants, mutually exclusive expression of Bw4 and Bw6 epitopes in naturally occurring HLA class 1 molecules may reflect evolutionary pressure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523516

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  A structurally based approach to determine HLA compatibility at the humoral immune level.

Authors:  Rene J Duquesnoy
Journal:  Hum Immunol       Date:  2006-09-01       Impact factor: 2.850

2.  Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells.

Authors:  Richard Apps; Zhaojing Meng; Gregory Q Del Prete; Jeffrey D Lifson; Ming Zhou; Mary Carrington
Journal:  J Immunol       Date:  2015-03-09       Impact factor: 5.422

Review 3.  Conformational changes in MHC class I molecules. Antibody, T-cell receptor, and NK cell recognition in an HLA-B7 model system.

Authors:  K D Smith; Z B Kurago; C T Lutz
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

4.  Differential contribution of TAP and tapasin to HLA class I antigen expression.

Authors:  Alan Belicha-Villanueva; Sarah McEvoy; Kelly Cycon; Soldano Ferrone; Sandra O Gollnick; Naveen Bangia
Journal:  Immunology       Date:  2008-01-11       Impact factor: 7.397

5.  Human leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell lines, determined using single antigen beads to characterize allotype specificities of anti-HLA antibodies.

Authors:  Richard Apps; Shawn P Murphy; Raymond Fernando; Lucy Gardner; Tashmeeta Ahad; Ashley Moffett
Journal:  Immunology       Date:  2009-05       Impact factor: 7.397

Review 6.  Human leukocyte antigen Bw4 and Bw6 epitopes recognized by antibodies and natural killer cells.

Authors:  Charles T Lutz
Journal:  Curr Opin Organ Transplant       Date:  2014-08       Impact factor: 2.640

7.  Enrichment of variations in KIR3DL1/S1 and KIR2DL2/L3 among H1N1/09 ICU patients: an exploratory study.

Authors:  David La; Chris Czarnecki; Hani El-Gabalawy; Anand Kumar; Adrienne F A Meyers; Nathalie Bastien; J Neil Simonsen; Francis A Plummer; Ma Luo
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

8.  HLA-DQ-Specific Recombinant Human Monoclonal Antibodies Allow for In-Depth Analysis of HLA-DQ Epitopes.

Authors:  Suzanne Bezstarosti; Cynthia S M Kramer; Marry E I Franke-van Dijk; Manon Vergunst; Kim H Bakker; Merve Uyar-Mercankaya; Rico Buchli; Dave L Roelen; Johan W de Fijter; Frans H J Claas; Sebastiaan Heidt
Journal:  Front Immunol       Date:  2022-01-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.